grant
Selective B Cell Depletion Using Engineered T Cells As A Curative Treatment For Acquired Thrombotic Thrombocytopenic Purpura
Organization UNIVERSITY OF PENNSYLVANIALocation PHILADELPHIA, UNITED STATESPosted 15 Jun 2025Deadline 31 Mar 2029
NIHUS FederalResearch GrantFY20252019 novel corona virus2019 novel coronavirus2019-nCoVADAMTSAbscissionAcuteAcute B-Lymphocytic LeukemiaAdrenal Cortex HormonesAffectAnemiaAnti-CD20 AntibodyAntibodiesAntigensAssayAutoantibodiesAutoantibody bindingAutoantibody reactivityAutoantigensAutoimmuneAutoimmune DiseasesAutoimmune StatusAutoimmune ThrombocytopeniasAutoimmune Thrombocytopenic PurpuraAutoimmunityAutologous AntigensAvidityB blood cellsB cellB cell progenitor acute lymphoblastic leukemiaB cellsB-ALLB-Cell Acute Lymphocytic LeukemiaB-Cell Acute Lymphoblastic LeukemiaB-Cell Lymphoblastic LeukemiaB-CellsB-LymphocytesB-cellB-cell ALLB-cell precursor acute lymphoblastic leukemiaBCR geneBCR1BindingBioassayBiological AssayBiophysicsBloodBlood ClottingBlood PlasmaBlood PlateletsBlood Reticuloendothelial SystemBlood VesselsBlood coagulationBody TissuesBreakpoint Cluster RegionC2B8 Monoclonal AntibodyCAR T cell therapyCAR T cellsCAR T therapyCAR modified T cellsCAR-TCAR-TsCD19CD19 geneCOVID-19 virusCOVID19 virusCell BodyCell FunctionCell PhysiologyCell ProcessCellsCellular FunctionCellular PhysiologyCellular ProcessCellular immunotherapyCessation of lifeClinicalClinical Treatment MoabClinical TrialsClone CellsCo-cultureCoV-2CoV2CocultivationCocultureCoculture TechniquesCorticoidsCorticosteroidsD pneumoniaeD. pneumoniaeDataDeathDevelopmentDimensionsDiplococcus pneumoniaeEngineeringEsteroproteasesExcisionExternal DomainExtirpationExtracellular DomainFaceGenesGoalsGrantHumanHumoral ImmunitiesIdiopathic Thrombocytopenic PurpuraImmuneImmune GlobulinsImmune TargetingImmune mediated therapyImmune systemImmune thrombocytopeniaImmunesImmunizationImmunodominant Antigenic DeterminantsImmunodominant DeterminantsImmunodominant DomainsImmunodominant EpitopesImmunodominant RegionsImmunodominant SitesImmunoglobulinsImmunologic ModelImmunological ModelsImmunologically Directed TherapyImmunosuppressionImmunosuppression EffectImmunosuppressive EffectImmunotherapyIn VitroInfectionInflammatory Muscle DiseasesInflammatory MyopathyIschemiaLeadLengthLifeLupusLupus Erythematosus DisseminatusMHC ReceptorMabTheraMajor Histocompatibility Complex ReceptorMarrow plateletMediatingMemoryMemory B CellMemory B-LymphocyteMoAb CD20Modern ManMolecular InteractionMonoclonal AntibodiesMonoclonal Antibody CD20MorbidityMorbidity - disease rateMorphologyMoschkowitz DiseaseMyasthenia GravisMyositisOrganPathogenicityPatientsPb elementPemphigusPeptidasesPeptide HydrolasesPhasePlasmaPlasma ExchangePlasma SerumPlasmapheresisPlatelet ActivationPlatelet aggregationPlateletsPneumococcusPre-B-Cell LeukemiaPreclinical dataPrecursor B Lymphoblastic LeukemiaProductionProtease GeneProteasesProteinasesProteinsProteolytic EnzymesReceptor ProteinRecommendationRefractoryRelapseRemovalReticuloendothelial System, Serum, PlasmaRistocetin CofactorRistocetin-Willebrand FactorRituxanS pneumoniaeS. pneumoniaeSARS corona virus 2SARS-CO-V2SARS-COVID-2SARS-CoV-2SARS-CoV2SARS-associated corona virus 2SARS-associated coronavirus 2SARS-coronavirus-2SARS-related corona virus 2SARS-related coronavirus 2SARSCoV2SLESafetySelf-AntigensSevere Acute Respiratory Coronavirus 2Severe Acute Respiratory Distress Syndrome CoV 2Severe Acute Respiratory Distress Syndrome Corona Virus 2Severe Acute Respiratory Distress Syndrome Coronavirus 2Severe Acute Respiratory Syndrome CoV 2Severe Acute Respiratory Syndrome-associated coronavirus 2Severe Acute Respiratory Syndrome-related coronavirus 2Severe acute respiratory syndrome associated corona virus 2Severe acute respiratory syndrome coronavirus 2Severe acute respiratory syndrome related corona virus 2SpecificityStreptococcus pneumoniaeStructureSubcellular ProcessSurgical RemovalSystemic Lupus ErythematosusSystemic Lupus ErythematousSystemic Lupus ErythmatosusSystemic SclerodermaSystemic SclerosisT cell based immune therapyT cell based therapeuticsT cell based therapyT cell directed therapiesT cell immune therapyT cell immunotherapyT cell receptor based immunotherapyT cell receptor cellular immunotherapyT cell receptor engineered therapyT cell receptor immunotherapyT cell targeted therapeuticsT cell therapyT cell treatmentT cell-based immunotherapyT cell-based treatmentT cells for CART cellular immunotherapyT cellular therapyT lymphocyte based immunotherapyT lymphocyte based therapyT lymphocyte therapeuticT lymphocyte treatmentT-Cell ActivationT-Cell Antigen ReceptorsT-Cell ReceptorT-Cell Receptor TherapyT-Cell Receptor TreatmentT-Cell Receptor based TherapyT-Cell Receptor based TreatmentT-CellsT-LymphocyteT-cell therapeuticsT-cell transfer therapyTCR T cell immunotherapyTCR T cell therapyTCR TherapyTCR based T cell immunotherapyTCR based TherapyTCR based immune therapyTCR based immunotherapyTCR based treatmentTCR immunotherapyTestingTherapeuticTherapeutic Plasma ExchangeTherapeutic PlasmapheresisThrombocytesThrombosisThrombotic Thrombocytopenic PurpuraThrombotic Thrombopenic PurpuraThrombusTissuesVariantVariationWerlhof's DiseaseWorkWuhan coronavirusactivate T cellsadoptive T cell transferadoptive T lymphocyte transferadoptive T-cell therapyanti-CD20antibody-based immunityautoimmune antibodyautoimmune conditionautoimmune disorderautoimmunity diseaseautoreactive antibodybiophysical analysisbiophysical foundationbiophysical principlesbiophysical sciencesbiophysical studiescell-based immunotherapychimeric antigen T cell receptorchimeric antigen receptorchimeric antigen receptor (CAR) T cell therapychimeric antigen receptor (CAR) T cellschimeric antigen receptor Tchimeric antigen receptor T cell therapychimeric antigen receptor T cellschimeric antigen receptor T therapychimeric antigen receptor fusion protein T-cellschimeric antigen receptor modified T cellsclinical developmentclinical efficacycomparable efficacycomparative efficacycompare efficacycoronavirus disease 2019 viruscoronavirus disease-19 viruscurative interventioncurative therapeuticcurative therapycurative treatmentsdesigndesigningdetermine efficacydevelopmentaldisseminated lupus erythematosusefficacy analysisefficacy assessmentefficacy determinationefficacy evaluationefficacy examinationengineered T cellsevaluate efficacyexamine efficacyexperiencefacesfacialflugenetically engineered T-cellshCoV19heavy metal Pbheavy metal leadimmune cell therapyimmune suppressionimmune suppressive activityimmune suppressive functionimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune thrombocytopenic purpuraimmune-based therapiesimmune-based treatmentsimmuno therapyimmunogenimmunological synapseimmunosuppressive activityimmunosuppressive functionimmunosuppressive responsein vitro Assayin vivoinjury to organsinnovateinnovationinnovativeinsightlead candidatemAbsmonoclonal Absmortalitymouse modelmurine modelnCoV2novelorgan injurypre-clinicalpre-clinical evaluationpreclinicalpreclinical evaluationpreclinical findingspreclinical informationprogressive systemic sclerosisprototypereceptorrelapse patientsresectionresponserituximabsafety assessmentself reactive antibodystandard of caresuperresolution imagingsystemic lupus erythematosistherapeutic T-cell platformthromboticthrombotic diseasethrombotic disorderthymus derived lymphocytetraditional therapytransgenic T- cellsvascularvon Willebrand Factorvon Willebrand Protein
Description preview
Project Summary
Immune thrombotic thrombocytopenic purpura (iTTP) is a life-threatening thrombotic
microangiopathy characterized by thrombosis due to dysregulated platelet activation. iTTP
results from autoantibodies directed against ADAMTS13, a plasma protease that regulates
platelet activation via cleavage of von Willebrand Factor (vWF)…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click